Roughly 90% of clinical trial protocols still exist as unstructured Word documents, according to TransCelerate BioPharma's October 2025 update. The Schedule of Activities sits at the center of that problem: a table full of merged cells, footnotes, and conditional logic that humans read easily but computers cannot parse reliably. Every protocol amendment that changes a visit window or procedure triggers manual re-keying into EDC, CTMS, and SDTM systems, turning a single change into weeks of downstream rework.
The Unified Study Definitions Model, or USDM, is the CDISC standard built to fix that. Instead of a static table, USDM represents the schedule as linked data: timepoints, activities, and conditions that software can read, validate, and propagate automatically. A recent analysis found protocols now average 3.3 amendments each, with a single Phase III amendment costing a median $535,000 to implement over 260 days. USDM does not eliminate amendments, but it removes the re-transcription step that makes each one expensive.
CDISC released USDM version 4.0 in June 2025, and the FDA finalized its ICH M11 protocol guidance in May 2026. The two standards are aligned but distinct: M11 governs the protocol document structure, while USDM governs the underlying study design data. For site coordinators, the practical difference shows up as consistent, system-generated visit checklists instead of discrepancies between what the protocol says and what the EDC system shows.